Evidence map›Paper›PMID 37039559›Full record

ArticleThe American journal of sports medicine2023

Proteomic Analyses of Autologous Chondrocyte Implantation Plasma Highlight Cartilage Acidic Protein 1 as a Candidate for Preclinical Screening.

Charlotte H Hulme, Mandy J Peffers, Sally Roberts, Pete Gallacher, Paul Jermin, Karina T Wright

Open access · hybridAbstract read
In one paragraph

Article in The American journal of sports medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Charlotte H HulmeCentre for Regenerative Medicine Research, School of Pharmacy and Bioengineering, Keele University, Keele, UK.
Mandy J PeffersInstitute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Sally RobertsCentre for Regenerative Medicine Research, School of Pharmacy and Bioengineering, Keele University, Keele, UK.
Pete GallacherRobert Jones and Agnes Hunt Orthopaedic Hospital Foundation Trust, Oswestry, UK.
Paul JerminRobert Jones and Agnes Hunt Orthopaedic Hospital Foundation Trust, Oswestry, UK.
Karina T WrightCentre for Regenerative Medicine Research, School of Pharmacy and Bioengineering, Keele University, Keele, UK.
Robert Jones and Agnes Hunt Orthopaedic Hospital · GBKeele University · GBUniversity of Liverpool · GB

Funding

Medical Research Council MR/N02706X/1Medical Research Council MR/P020941/1Medical Research Council MR/S015167/1Versus Arthritis 20815Versus Arthritis 21156Wellcome TrustWellcome Trust 107471/Z/15/Z
6 · The paper itself

Abstract

backgroundStratification is required to ensure that only patients likely to benefit receive autologous chondrocyte implantation (ACI). It would be advantageous to identify biomarkers to predict ACI outcome that are measurable in blood, avoiding the need for an invasive synovial fluid harvest. PURPOSE: To assess if proteomic analyses can be used to identify novel candidate blood biomarkers in individuals who respond well or poorly to ACI. STUDY

designControlled laboratory study.

methodsIsobaric tagging for relative and absolute quantitation (iTRAQ) mass spectrometry was used to assess the proteome in plasma pooled from ACI responders (mean Lysholm improvement after ACI, 33; n = 10) or nonresponders (mean, -13; n = 10), collected at the time of surgery for cartilage harvest (stage 1) or implantation of culture-expanded chondrocytes (stage 2). An alternative proteomic method, label-free quantitation liquid chromatography-tandem mass spectrometry, was used to analyze plasma samples (majority matched to iTRAQ) individually. Differentially abundant proteins (±2.0-fold) were analyzed from both proteomic data sets, and markers of interest identified via pooled iTRAQ were validated via immunoassay of individual samples.

resultsProtein differences could be detected in the plasma preoperatively between ACI responders and nonresponders (16 proteins; ≥±2.0-fold change;

conclusionsThis study is the first to use proteomic techniques to profile the plasma of individuals treated with ACI. Despite iTRAQ analysis of pooled plasmas indicating that there are differences in the plasma proteome between responders and nonresponders to ACI, these findings were not replicated when assessed using an alternative nonpooled technique. This study highlights some of the difficulties in profiling the plasma proteome in an attempt to identify novel biomarkers. Regardless, cartilage acidic protein 1 has been identified as a protein candidate, which is detectable in plasma and can predict outcome to ACI before treatment. CLINICAL RELEVANCE: Candidate plasma protein biomarkers identified in this study have the potential to help determine which patients will be best suited to treatment with ACI.

Indexed as

Cartilage, ArticularChondrocytesBiomarkersCalcium-Binding ProteinsHumansKnee JointProteomeProteomicsTransplantation, AutologousBiomarkersCalcium-Binding ProteinsCRTAC1 protein, humanProteomeautologous chondrocyte implantationbiomarkersplasmapredictiveproteomics

Identifiers

PMID37039559
PMCPMC10155277
OpenAlexW4364353553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.